Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03695185 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

A Phase 2 study of Ulcerative Colitis (UC), sponsored by AbbVie.

Completed
Registry status
Phase 2
Development phase
42
Enrollment target
20
Study locations

NCT03695185 is a Phase 2 study of Ulcerative Colitis (UC) that has completed, run by AbbVie. The registered enrollment target is 42 participants, below the 762-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03695185, a Phase 2 study of Ulcerative Colitis (UC), has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 2
Development phase
42 participants
Enrollment target
20
Study locations

Study Summary

Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.

Conditions Studied

Ulcerative Colitis (UC)

Interventions

  • DRUG Ravagalimab 600 mg
  • DRUG Ravagalimab 300 mg

Study Locations (20)

California

  • Meridian Investigator Network /ID# 204646 - Huntington Beach
  • Meridian Investigator Network /ID# 218568 - Lakewood
  • TLC Clinical Research Inc /ID# 206626 - Los Angeles
  • Orange County Institute of Gastroenterology and Endoscopy /ID# 207405 - Mission Viejo
  • UC Davis Medical Center /ID# 209402 - Sacramento

Illinois

  • The University of Chicago DCAM /ID# 207086 - Chicago
  • Affinity Clinical Research /ID# 206211 - Oak Brook

Arizona

  • Banner University Medical Cent /ID# 208392 - Tucson

New Mexico

  • Univ New Mexico /ID# 208817 - Albuquerque

Pennsylvania

  • Penn Presbyterian Medical Center /ID# 206826 - Philadelphia

Tennessee

  • Vanderbilt University Medical Center /ID# 204670 - Nashville

Texas

  • Clinical Associates in Research Therapeutics of America, LLC /ID# 204689 - San Antonio

Ontario

  • Mount Sinai Hospital /ID# 206180 - Toronto

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2019-03-26
Est. Completion 2022-01-10
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03695185

The ClinicalTrials.gov registry entry for NCT03695185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 762-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (94% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 2 interventions - of which Ravagalimab 600 mg is the first listed.

NCT03695185 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, Arizona.

Frequently Asked Questions

What is clinical trial NCT03695185 about?

NCT03695185 is a clinical study titled "A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy". Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.

What is the current status of trial NCT03695185?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2019-03-26. Estimated completion is 2022-01-10.

What conditions does trial NCT03695185 study?

This clinical trial studies the following conditions: Ulcerative Colitis (UC).

What interventions are being tested in trial NCT03695185?

The interventions under investigation include: Ravagalimab 600 mg (DRUG), Ravagalimab 300 mg (DRUG).

Who is sponsoring clinical trial NCT03695185?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03695185 being conducted?

This trial has 20 study locations across Arizona, California, Illinois, New Mexico, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis (UC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis (UC)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.